Zentalis Pharmaceuticals Inc
Research Zentalis Pharmaceuticals Inc (ZNTL) on Bullrun: market cap USD 278.07M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZNTL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 278.07M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 42.29M
- Free cash flow-USD 37.24M
Valuation Snapshot
latest market cap is USD 278.07M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 137.06M | -USD 125.25M | n/a | -1.91 | USD 36.00M | USD 35.70M | USD 216.20M |
| FY2024 | USD 67.43M | -USD 165.87M | -USD 171.08M | n/a | -2.33 | USD 33.90M | USD 39.58M | USD 337.19M |
| FY2023 | USD 0 | -USD 292.31M | -USD 208.41M | n/a | -4.47 | USD 28.04M | USD 43.15M | USD 437.28M |
| FY2022 | USD 0 | -USD 236.81M | -USD 166.30M | n/a | -4.48 | USD 43.07M | USD 46.81M | USD 433.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 278.07M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 93.27M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 215.99M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.07B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.15B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.82B | n/a | n/a | n/a |
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zentalis Pharmaceuticals Inc's market cap?
Zentalis Pharmaceuticals Inc's market capitalization is USD 278.07M.
What does Zentalis Pharmaceuticals Inc do?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.